drugset / Trial / NCT01840943

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

NCT01840943

Phase 3 Terminated 32 enrolled Xian-Janssen Pharmaceutical Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the effectiveness between CAELYX and topotecan hydrochloride (HCl) in Chinese participants with recurrent epithelial ovarian carcinoma following failure of first-line, platinum-based chemotherapy, who have received no more than one prior platinum-based regimen therapy.

Timeline

Start
2013-06
Primary completion
2014-05
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Comparator Topotecan Small molecule 1.25 mg/m2 Intravenous